Literature DB >> 28379303

Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia.

Andrew E Arrant1, Anthony J Filiano1, Daniel E Unger1, Allen H Young1, Erik D Roberson1.   

Abstract

Loss-of-function mutations in progranulin (GRN), a secreted glycoprotein expressed by neurons and microglia, are a common autosomal dominant cause of frontotemporal dementia, a neurodegenerative disease commonly characterized by disrupted social and emotional behaviour. GRN mutations are thought to cause frontotemporal dementia through progranulin haploinsufficiency, therefore, boosting progranulin expression from the intact allele is a rational treatment strategy. However, this approach has not been tested in an animal model of frontotemporal dementia and it is unclear if boosting progranulin could correct pre-existing deficits. Here, we show that adeno-associated virus-driven expression of progranulin in the medial prefrontal cortex reverses social dominance deficits in Grn+/- mice, an animal model of frontotemporal dementia due to GRN mutations. Adeno-associated virus-progranulin also corrected lysosomal abnormalities in Grn+/- mice. The adeno-associated virus-progranulin vector only transduced neurons, suggesting that restoring neuronal progranulin is sufficient to correct deficits in Grn+/- mice. To further test the role of neuronal progranulin in the development of frontotemporal dementia-related deficits, we generated two neuronal progranulin-deficient mouse lines using CaMKII-Cre and Nestin-Cre. Measuring progranulin levels in these lines indicated that most brain progranulin is derived from neurons. Both neuronal progranulin-deficient lines developed social dominance deficits similar to those in global Grn+/- mice, showing that neuronal progranulin deficiency is sufficient to disrupt social behaviour. These data support the concept of progranulin-boosting therapies for frontotemporal dementia and highlight an important role for neuron-derived progranulin in maintaining normal social function.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  FTD; dementia; experimental models; gene therapy; progranulin

Mesh:

Substances:

Year:  2017        PMID: 28379303      PMCID: PMC5965303          DOI: 10.1093/brain/awx060

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  74 in total

1.  Core features of frontotemporal dementia recapitulated in progranulin knockout mice.

Authors:  N Ghoshal; J T Dearborn; D F Wozniak; N J Cairns
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

2.  Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice.

Authors:  Y Tanaka; T Matsuwaki; K Yamanouchi; M Nishihara
Journal:  Neuroscience       Date:  2013-07-02       Impact factor: 3.590

3.  Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety.

Authors:  F Tronche; C Kellendonk; O Kretz; P Gass; K Anlag; P C Orban; R Bock; R Klein; G Schütz
Journal:  Nat Genet       Date:  1999-09       Impact factor: 38.330

4.  PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue.

Authors:  Toshiya Matsubara; Ayako Mita; Kohtaro Minami; Tetsuya Hosooka; Sohei Kitazawa; Kenichi Takahashi; Yoshikazu Tamori; Norihide Yokoi; Makoto Watanabe; Ei-Ichi Matsuo; Osamu Nishimura; Susumu Seino
Journal:  Cell Metab       Date:  2012-01-04       Impact factor: 27.287

5.  Brain progranulin expression in GRN-associated frontotemporal lobar degeneration.

Authors:  Alice S Chen-Plotkin; Jiping Xiao; Felix Geser; Maria Martinez-Lage; Murray Grossman; Travis Unger; Elisabeth M Wood; Vivianna M Van Deerlin; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2009-08-02       Impact factor: 17.088

6.  Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease.

Authors:  M Hoefer; S C Allison; G F Schauer; J M Neuhaus; J Hall; J N Dang; M W Weiner; B L Miller; H J Rosen
Journal:  Brain       Date:  2008-05-20       Impact factor: 13.501

Review 7.  Granulins: the structure and function of an emerging family of growth factors.

Authors:  A Bateman; H P Bennett
Journal:  J Endocrinol       Date:  1998-08       Impact factor: 4.286

Review 8.  Progranulin: at the interface of neurodegenerative and metabolic diseases.

Authors:  Andrew D Nguyen; Thi A Nguyen; Lauren Herl Martens; Laura L Mitic; Robert V Farese
Journal:  Trends Endocrinol Metab       Date:  2013-09-10       Impact factor: 12.015

Review 9.  Mechanisms of granulin deficiency: lessons from cellular and animal models.

Authors:  Gernot Kleinberger; Anja Capell; Christian Haass; Christine Van Broeckhoven
Journal:  Mol Neurobiol       Date:  2012-12-13       Impact factor: 5.590

10.  Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Jackalina M Van Kampen; David Baranowski; Denis G Kay
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

View more
  25 in total

1.  Genetic Regulation of Neuronal Progranulin Reveals a Critical Role for the Autophagy-Lysosome Pathway.

Authors:  Lisa P Elia; Amanda R Mason; Amela Alijagic; Steven Finkbeiner
Journal:  J Neurosci       Date:  2019-01-29       Impact factor: 6.167

Review 2.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.

Authors:  Yazhou Cui; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2019-01-30       Impact factor: 7.638

3.  AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity.

Authors:  Defne A Amado; Julianne M Rieders; Fortunay Diatta; Pilar Hernandez-Con; Adina Singer; Jordan T Mak; Junxian Zhang; Eric Lancaster; Beverly L Davidson; Alice S Chen-Plotkin
Journal:  Mol Ther       Date:  2018-11-17       Impact factor: 11.454

4.  Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.

Authors:  Andrew E Arrant; Anthony J Filiano; Aashka R Patel; Madelyn Q Hoffmann; Nicholas R Boyle; Shreya N Kashyap; Vincent C Onyilo; Allen H Young; Erik D Roberson
Journal:  Neurobiol Dis       Date:  2018-11-15       Impact factor: 5.996

5.  Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression.

Authors:  Carlos Moreno-Yruela; Daniel M Fass; Chialin Cheng; Joachim Herz; Christian A Olsen; Stephen J Haggarty
Journal:  ACS Chem Neurosci       Date:  2019-08-05       Impact factor: 4.418

6.  Progranulin associates with Rab2 and is involved in autophagosome-lysosome fusion in Gaucher disease.

Authors:  Xiangli Zhao; Rossella Liberti; Jinlong Jian; Wenyu Fu; Aubryanna Hettinghouse; Ying Sun; Chuan-Ju Liu
Journal:  J Mol Med (Berl)       Date:  2021-08-27       Impact factor: 4.599

7.  High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing.

Authors:  Robert N Plasschaert; Mark P DeAndrade; Fritz Hull; Quoc Nguyen; Tara Peterson; Aimin Yan; Mariana Loperfido; Cristina Baricordi; Luigi Barbarossa; John K Yoon; Yildirim Dogan; Zeenath Unnisa; Jeffrey W Schindler; Niek P van Til; Luca Biasco; Chris Mason
Journal:  Mol Ther       Date:  2022-05-25       Impact factor: 12.910

8.  Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.

Authors:  Andrew E Arrant; Vincent C Onyilo; Daniel E Unger; Erik D Roberson
Journal:  J Neurosci       Date:  2018-01-29       Impact factor: 6.167

Review 9.  Approaches to develop therapeutics to treat frontotemporal dementia.

Authors:  Lisa P Elia; Terry Reisine; Amela Alijagic; Steven Finkbeiner
Journal:  Neuropharmacology       Date:  2020-01-08       Impact factor: 5.250

10.  New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.

Authors:  Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton
Journal:  Alzheimers Dement       Date:  2020-01-06       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.